Investigational immunomodulatory therapies for COVID-19

M. Assi, K. M. Koshy, W. El Atrouni, K. Burke, M. Berg, A. Opardija, Z. Temesgen

Research output: Contribution to journalReview articlepeer-review

Abstract

A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov, and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.

Original languageEnglish (US)
Pages (from-to)711-729
Number of pages19
JournalDrugs of the Future
Volume46
Issue number9
DOIs
StatePublished - Sep 2021

Keywords

  • Anti-IL-1 agents
  • Anti-IL-6 agents
  • CCR2 antagonists
  • CCR5 antagonists
  • Corticosteroids
  • COVID-19
  • GM-CSF
  • Immunomodulatory therapies
  • Interferons
  • Janus kinase inhibitors
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Investigational immunomodulatory therapies for COVID-19'. Together they form a unique fingerprint.

Cite this